MHLW Approves Otsuka Samsca
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labour and Welfare approved Otsuka Pharmaceutical's Samsca (tolvaptan) for the treatment of excess water retention in patients with cardiac failure when other diuretics are ineffective
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.